A detailed history of Pro Share Advisors LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 44,658 shares of TSHA stock, worth $94,674. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,658
Previous 11,545 286.82%
Holding current value
$94,674
Previous $25,000 256.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.01 - $2.46 $66,557 - $81,457
33,113 Added 286.82%
44,658 $89,000
Q2 2024

Aug 13, 2024

SELL
$2.04 - $4.17 $3,178 - $6,496
-1,558 Reduced 11.89%
11,545 $25,000
Q1 2024

May 08, 2024

BUY
$1.43 - $3.25 $1,654 - $3,760
1,157 Added 9.69%
13,103 $37,000
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $15,888 - $34,404
11,946 New
11,946 $21,000
Q1 2022

May 10, 2022

SELL
$5.22 - $11.86 $54,120 - $122,964
-10,368 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$11.43 - $19.2 $118,506 - $199,065
10,368 New
10,368 $121,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $103M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.